lipids

Inhibition of ceramide metabolism combats enzalutamide resistance in prostate cancer

Inhibition of ceramide metabolism combats enzalutamide resistance in prostate cancer

Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase.
Lin HM, Mak B, Yeung N, Huynh K, Meikle TG, Mellett NA, Kwan EM, Fettke H, Tran B, Davis ID, Mahon KL, Zhang A, Stockler MR, Briscoe K, Marx G, Crumbaker M, Stricker PD, Du P, Yu J, Jia S, Scheinberg T, Fitzpatrick M, Bonnitcha P, Sullivan DR, Joshua AM, Azad AA, Butler LM, Meikle PJ, Horvath LG.
EBioMedicine. 2021 Oct 14;72:103625. doi: 10.1016/j.ebiom.2021.103625. PMID: 34656931.
Contact: Lisa Butler

Study extends evidence on circulating fats and clinical outcomes for men with prostate cancer

Study extends evidence on circulating fats and clinical outcomes for men with prostate cancer

Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer. Lin HM, Huynh K, Kohli M, Tan W, Azad AA, Yeung N, Mahon KL, Mak B, Sutherland PD, Shepherd A, Mellett N, Docanto M, Giles C, Centenera MM, Butler LM, Meikle PJ, Horvath LG.
Prostate Cancer Prostatic Dis. 2021 Mar 21. doi: 10.1038/s41391-021-00338-z.
Contact: Lisa Butler

ELOVL5: Inching closer to a new therapeutic strategy for prostate cancer

ELOVL5: Inching closer to a new therapeutic strategy for prostate cancer

ELOVL5 is a critical and targetable fatty acid elongase in prostate cancer
Centenera MM, Scott JS, Machiels J, Nassar ZD, Miller DC, Zininos I, Dehairs J, Burvenich IJG, Zadra G, Chetta P, Bango C, Evergren E, Ryan NK, Gillis JL, Mah CY, Tieu T, Hanson AR, Carelli R, Bloch K, Panagopoulos V, Waelkens E, Derua R, Williams ED, Evdokioou A, Cifuentes-Rius A, Voelcker NH, Mills IG, Tilley WD, Scott AM, Loda M, Selth LA, Swinnen JV, Butler LM. Cancer Res. 2021 Feb 5:canres.2511.2020. doi: 10.1158/0008-5472.CAN-20-2511.
Contact: Maggie Centenera